Correa, Rodrigo de SouzaFreire, VitóriaBarbosa, Marília Imaculada FrazãoBezerra, Daniel PereiraBomfim, Larissa MendesMoreira, Diogo Rodrigo de MagalhãesSoares, Milena Botelho PereiraEllena, Javier AlcidesBatista, Alzir Azevedo2019-05-082019-05-082018CORREA, R. de S. et al. Ru(II)–thyminate complexes : new metallodrug candidates against tumor cells. New Journal of Chemistry, v. 42, p. 6794--6802, 2018. Disponível em: <https://pubs.rsc.org/en/content/articlelanding/2018/nj/c7nj04368f#!divAbstract>. Acesso em: 7 mar. 2019.1369-9261http://www.repositorio.ufop.br/handle/123456789/11226Herein, we used thymine (HThy) as a ligand to form two new ruthenium(II) complexes with formula [Ru(PPh3)2(Thy)(bipy)]PF6 (1) and [Ru(Thy)(bipy)(dppb)]PF6 (2). The complexes were characterized by spectroscopic, spectrometric and X-ray crystallography analyses. Complexes 1 and 2 can interact with ctDNA presenting binding constants, Kb, of 0.4 and 1.2 × 103 M−1, respectively. Their cytotoxic activities towards tumor cell lines (B16-F10, HepG2, K562 and HL-60) and non-tumor cells (PBMCs) were evaluated using the Alamar blue assay. Complex 1 exhibits high cytotoxicity against tumor cells, showing IC50 values of 0.01 and 1.81 μM against the HL-60 and HepG2 cell lines, respectively. Therefore, compound 1 can be considered as a promising antitumor metallodrug.en-USrestritoArtigo publicado em periodicohttps://pubs.rsc.org/en/content/articlelanding/2018/NJ/C7NJ04368F#!divAbstracthttp://doi.org/10.1039/c7nj04368f